Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellSource CoTSE:4880 +0.33%70 5-Year Yield-on-Cost % is 1.61 as of Aug. 05, 2026, which is 156% above its 10-year median of 0.63. GuruFocus rates TSE:4880 with a GF Score™ of 70/100 and a GF Value™ of 円779.27 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 150 Biotechnology companies, CellSource Co ranks worse than 52.67% on this metric.
CellSource Co's yield on cost for the quarter that ended in Apr. 2026 was 1.61.
The historical rank and industry rank for CellSource Co's 5-Year Yield-on-Cost % or its related term are showing as below:
TSE:4880'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.29 Med: 0.63 Max: 1.66
Current: 1.61
During the past 9 years, CellSource Co's highest Yield on Cost was 1.66. The lowest was 0.29. And the median was 0.63.
TSE:4880's 5-Year Yield-on-Cost % is ranked worse than 52.67% of 150
companies
in the Biotechnology industry
Industry Median: 1.69
vs TSE:4880: 1.61
CellSource Co (TSE:4880) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
CellSource Co 5-Year Yield-on-Cost % Related Terms
TSE:4880 vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, CellSource Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where CellSource Co's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of CellSource Co is calculated as
CellSource Co (TSE:4880) has a 5-Year Yield-on-Cost % of 1.61 as of Aug. 05, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on CellSource Co and its competitors. This is 156% above median its historical median of 0.63. Over the past decade, CellSource Co's 5-Year Yield-on-Cost % has ranged from 0.29 to 1.66. According to the industry distribution chart, CellSource Co ranks #79 out of 150 companies in the Biotechnology industry, placing it in the top 52.7%.
Is CellSource Co's 5-Year Yield-on-Cost % too high?
CellSource Co's current 5-Year Yield-on-Cost % of 1.61 is 156% above median its 10-year median of 0.63. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 1.66. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.69. CellSource Co's value of 1.61 is 4.7% below this industry median. Based on the distribution chart, CellSource Co ranks #79 out of 150 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CellSource Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #79 out of 150 companies for 5-Year Yield-on-Cost %. This places CellSource Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.69. CellSource Co's value of 1.61 is 4.7% below this benchmark. Historically, CellSource Co's own 5-Year Yield-on-Cost % has ranged from 0.29 to 1.66 over the past decade. While the company's 10-year median is 0.63 vs. the industry median of 1.69, CellSource Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.69, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellSource Co's current 5-Year Yield-on-Cost % of 1.61 is 4.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on CellSource Co and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellSource Co's current 5-Year Yield-on-Cost % is 1.61, which is 156% above median its own 10-year median of 0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円779.27, compared to a current price of 円308.00 — trading 60.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.61, which is 156% above median its 10-year median of 0.63 and 4.7% below the Biotechnology industry median of 1.69. CellSource Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current 5-Year Yield-on-Cost % is 1.61 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円308.00 is trading 60.5% below its estimated GF Value™ of 円779.27.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
5-Year Yield-on-Cost %: 1.61 (156% above median its 10-year median of 0.63)
GF Value™: 円779.27 vs. price of 円308.00 (60.5% below fair value)
Industry Position: 4.7% below the Biotechnology median (#79 of 150)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
70GF Score
Get the complete analysis for TSE:4880
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
